Li XL, Li M, Yang H, Tian J, Shi ZW, Wang LZ, Song K. Chronic myelogenous leukemia secondary to colon cancer: A case report. World J Gastrointest Oncol 2025; 17(4): 102021 [DOI: 10.4251/wjgo.v17.i4.102021]
Corresponding Author of This Article
Kui Song, Professor, Department of Hematology, The First Affiliated Hospital of Jishou University, No. 26 Century Avenue, Qianzhou, Jishou 416000, Hunan Province, China. songkui2001@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 102021 Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102021
Chronic myelogenous leukemia secondary to colon cancer: A case report
Xiao-Lan Li, Min Li, Hua Yang, Juan Tian, Zi-Wei Shi, Ling-Zhi Wang, Kui Song
Xiao-Lan Li, Hua Yang, Juan Tian, Zi-Wei Shi, Kui Song, Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China
Min Li, Ling-Zhi Wang, Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China
Author contributions: Song K and Li XL conceived and designed the study; Li XL collected all relevant data of patients from the database and drafted the manuscript; Li M was responsible for medication guidance; Shi ZW and Wang LZ analyzed the data. Song K revised the manuscript; Yang H and Tian J participated in making the pathological diagnosis; and all authors confirmed the authenticity of all the raw data, and have read and approved the final manuscript.
Supported by the Innovation Platform and talent program of Hunan Province, No. 2021SK4050; and the Natural Science Foundation of Hunan Province, No. 2023JJ30608 and No. 2023JJ30609.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kui Song, Professor, Department of Hematology, The First Affiliated Hospital of Jishou University, No. 26 Century Avenue, Qianzhou, Jishou 416000, Hunan Province, China. songkui2001@163.com
Received: October 5, 2024 Revised: January 26, 2025 Accepted: February 18, 2025 Published online: April 15, 2025 Processing time: 171 Days and 0.9 Hours
Abstract
BACKGROUND
Colon cancer is a common malignancy of the digestive tract. An estimated 1148515 new cases of colon cancer were reported in 2020 worldwide. Chronic myeloid leukemia (CML) is a malignant tumor formed by the clonal proliferation of bone marrow hematopoietic stem cells, with an annual incidence rate of 1-2 cases per 100000 people worldwide. Leukemia can be secondary to solid tumors, and vice versa. Reports on CML secondary malignant tumors account for 8.7% but CML secondary to malignancy is extremely rare. Therapy-related CML is a rare but potentially fatal adverse event of chemotherapy or radiotherapy. Herein, we report a case of CML with colon cancer and discuss this unique patient population. Our findings can provide effective raw data and guidance for the diagnosis of this clinical disease.
CASE SUMMARY
A 61-year-old male patient attended our hospital due to leukocytosis for 5 days. In February 2020, the patient was diagnosed with colon cancer and underwent radical surgery and conventional chemotherapy with a stable condition. He was diagnosis was CML-chronic phase (Sokal score of 0.72) after examination. He was treated with imatinib (400 mg daily). When his conditions improved, the patient was discharged from our hospital and visited the outpatient department for follow-up twice a month.
CONCLUSION
CML in patients with colon cancer is extremely rare. Secondary hematological tumors may be multifactorial, and the exact mechanism is currently unknown. Owing to the slow progression of the disease, patients with CML show no symptoms in the early stage. However, with disease progression, obvious but non-specific symptoms may appear, including fever, anemia, bleeding tendency, and hypertrophy. Therefore, complete blood count monitoring for routine examination is recommended after cancer treatment for early detection of occult hematological tumors.
Core Tip: We report a case of chronic myelogenous leukemia secondary to colon cancer. Secondary hematological tumors may be multifactorial, and the exact mechanism is currently unknown. Owing to the slow progression of the disease, patients with chronic myelogenous leukemia show no symptoms in the early stage. However, with disease progression, obvious but non-specific symptoms may appear, including fever, anemia, bleeding tendency, and hypertrophy. Therefore, complete blood count monitoring for routine examination is recommended after cancer treatment for early detection of occult hematological tumors.
